Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats.

This work investigated the pharmacokinetics of a new N-phenylpiperazine derivative (LASSBio-581), active on dopaminergic system. LASSBio-581 plasma concentrations were determined in rats after bolus administration of 10mg/kg, i.v., 30 and 60 mg/kg, i.p. and p.o., by HPLC. Individual profiles were evaluated by non-compartmental and compartmental analysis using WinNonlin. Protein binding by ultrafiltration showed free fraction of 29+/-4%. The compound showed linear pharmacokinetics for the extravascular doses investigated. The oral bioavailability ( approximately 25%) was approximately half of the intra-peritoneal one ( approximately 47%). The 60 mg/kg oral dose showed an unusual profile with two peaks (1 and 6h). A two-compartment model better described all plasma profiles. The Vd (0.8+/-0.4l/kg) and the t(1/2) (1.2+/-0.4h) were smaller for i.v. than for the other routes. The CL(tot) was statistically similar for all three administration routes investigated (0.6+/-0.2l/(hkg)) (alpha=0.05). The compound distribution into different organs, evaluated in tissue homogenates after i.v. administration, showed a higher penetration in lungs (51.0%), followed by the brain (39.2%), where the half-life was three times bigger than in the other tissues (1.9h). The compound brain profile agreed with the central nervous system activity determined.     

基因重组人白细胞介素-2在小鼠的药物动力学和分布(英文)

lodogen法制备~(125)I-rlL-2,放射纯度95％,ⅳ后快速、慢速分布和消除T_(1/2)分别为<2,30—120和6—15h,AUC与剂量呈正比,血尿原药占81±13％,im生物利用度0.57,ⅳ后15min浓度顺序为肝>胆汁>肾>血>肾上腺>>血浆>肺>甲状腺>脾>小肠>肠系膜淋巴结>肠内容>卵巢>心>膀胱>胸腺>粪>肌肉>>睾丸>脑>脂肪,24 h排出80％第2天5％。     

Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species

Single and repeated dose experiments in mice, rats, dogs and monkeys are reported in this study to assess the pharmacokinetics and tissue distribution of rifametane, a new semi-synthetic rifamycin with the chemical formula 3-[(1-diethylaminoethylidene)azinomethyl]rifamycin SV (CAS 94168-98-6, SPA-S-565). All the kinetic tests were carried out in comparison with known rifamycin derivatives, as rifampicin (CAS 13292-46-1) or rifamycin SV (CAS 6998-60-3). Mice received single i.v. and oral administration of 10 mg/kg of rifametane or of rifampicin and serum samples were obtained up to 96 h after dosing. The two antibiotics showed similar peak of serum concentrations, but rifametane showed a longer half-life and higher AUC values. In an additional experiment, the tissue/serum ratio after the 10 mg/kg oral dose was lower than unity for lungs and kidneys, while the liver/serum ratio exceeded the unity at all sampling times. After 4 weeks of once weekly administration measurable serum and tissue concentrations were observed, and after twice weekly administration for the same time period some blood and tissue accumulation was seen. Rats were treated with a single intravenous injection of 20 mg/kg of rifametane or rifampicin and with single oral or i.m. administration of 60 mg/kg of rifametane or reference standards (rifampicin and rifamycin SV resp.), in two separate trials. The serum half-life of the test antibiotic after i.v. dose was 6 times longer than that of rifampicin and the serum concentrations of rifametane after oral and i.m. doses were higher and longer-lasting than those of the reference compounds. Repeated daily administrations of rifametane at three dose levels (3, 10, 30 mg/kg p.o.) for 4 weeks induced very high serum and liver concentrations. Dogs received a single oral dose of 1.25 mg/kg of rifametane or 2.5 mg/kg of rifampicin. The serum half-life of rifametane resulted 3 times longer than that of rifampicin. Remarkable serum and tissue concentrations were observed after 3-4 weeks of daily oral administration of rifametane at 3, 10, 30 mg/kg dose. Monkeys were given single oral or i.m. administration of 30 mg/kg of rifametane or reference standards (oral rifampicin and i.m. rifamycin SV). The serum concentrations after rifametane were higher and more sustained than those of reference compounds and the half-lives of the test antibiotic were about 2.5 (p.o.) to 6 times (i.m.) longer. The urine excretion of rifametane after a single intravenous dose in rats and a single oral dose in dogs was very low, while rifampicin had a little higher urine concentrations.     

头孢呋辛钠在小鼠体内的药代动力学及组织分布研究

目的：通过HPLC探讨注射用头孢呋辛钠在小鼠体内的药代动力学和组织分布。方法：小鼠单剂量背部推注头孢呋辛钠1000mg/kg,在不同时间取其血浆及各组织匀浆液经离心沉淀蛋白后,采用HPLC法测定其药代动力学及组织中药物浓度。结果：背部给药后血浆药—时曲线符合一室开放模型,头孢呋辛钠体内分布迅速,分布半衰期为0.6179h,消除半衰期为2.2098h,AUC为76.3199h.mg/mL,肺、肝脏及肾脏中药物浓度较高。结论：头孢呋辛钠在体内分布广、组织浓度高、消除半衰期。     

Pharmacokinetics, tissue distribution and placental permeability of tetrahydro-tetramethyl-naphthalenyl-propenyl benzoic acid (a retinoidal benzoic acid derivative) in hamsters

Tritiated tetrahydro-tetramethyl-naphthalenyl-propenyl benzoic acid (TTNPB; Ro 13-7410) was administered as a single oral bolus to pregnant hamsters (day 8) to determine the maternal plasma pharmacokinetic profile and peripheral tissue distribution patterns. Blood and tissue, including embryo or fetus, were collected at specific time intervals to 96 h and assayed for total radioactive compounds and/or parent retinoid. No lag time was required to describe retinoid absorption (t 1/2 pi = 1.2 h) with peak plasma levels at 2.4 h; the concentrations then declined with exponential elimination from the central compartment (t 1/2 e = 3 h). The maximum concentrations of circulating radioactive compound or metabolites after 100 micrograms/kg [3H]2-TTNPB occurred in liver greater than fetus greater than adrenal greater than lung approximately equal to kidney greater than plasma; after 1000 micrograms/kg, maternal liver accumulated the highest concentration followed by plasma greater than fetus = placenta = uterus. An unidentified, polar metabolite was detected in plasma at 0.5 h and by 12 h constituted greater than 90% of the total circulating radioactivity. TTNPB was absorbed and cleared more slowly, concentrated in the conceptus to a higher degree and possessed greater intrinsic activity than the naturally-occurring tetraene retinoids. These properties contribute to the marked teratogenic activity of TTNPB as compared to the tetraene retinoids.     

Pharmacokinetics and tissue distribution of psammaplin A, a novel anticancer agent, in mice

This study reports the pharmacokinetics and tissue distribution of a novel histone deacetylase and DNA methyltransferase inhibitor, psammaplin A (PsA), in mice. PsA concentrations were determined by a validated LC-MS/MS assay method (LLOQ 2 ng/mL). Following intravenous injection at a dose of 10 mg/kg in mice, PsA was rapidly eliminated, with the average half-life (t_{1/2, λn}) of 9.9 ± 1.4 min and the systemic clearance (CL_s) of 925.1 ± 570.1 mL/min. The in vitro stability of PsA was determined in different tissue homogenates. The average degradation t_1/2 of PsA in blood, liver, kidney and lung was found relatively short (≤ 12.8 min). Concerning the in vivo tissue distribution characteristics, PsA was found to be highly distributed to lung tissues, with the lung-to-serum partition coefficients (K_p) ranging from 49.9 to 60.2. In contrast, PsA concentrations in other tissues were either comparable with or less than serum concentrations. The high and specific lung targeting characteristics indicates that PsA has the potential to be developed as a lung cancer treatment agent.     

Pharmacokinetics and tissue distribution of the sesquiterpene alpha-humulene in mice

A quantitative study was undertaken to assess the plasma and tissue levels, tissue distribution and skin (ear) absorption of the sesquiterpene alpha-humulene, the main active constituent isolated from the plant Cordia verbenacea (Boraginaceae ), after oral, intravenous and topical administration in mice. The alpha-humulene levels were quantified by GC-MS analysis. The peak alpha-humulene concentration was achieved 15 min following its oral administration (150 mg/kg). Then, the alpha-humulene plasma concentration gradually decreased and it was almost undetectable at 2 hours after intravenous administration and 12 hours after oral administration. When the oil of C. verbenacea was given orally (1 g/kg), the peak alpha-humulene plasma concentration was observed after 30 min, being detectable only up to 2 h. The oral bioavailability of alpha-humulene was found to be 18 %. The half-lives of alpha-humulene were very short, 16.8 min after oral administration and 1.8 min after intravenous administration. However, the elimination half-lives were longer, 118.2 min and 55 min, for oral and intravenous routes, respectively. We also assessed the amount of alpha-humulene in some selected tissues at 0.5 and at 4 h after oral administration. We found a high amount of the compound in the liver, followed by the kidneys, heart, lungs, spleen and brain, 0.5 h after oral administration. Notably, the yield of alpha-humulene decreased significantly in all analyzed tissues, especially in the liver, 4 h after oral administration. Of note, 30 minutes after topical administration of Acheflan formulations (cream and aerosol) containing 0.5 % of C. verbenacea essential oil, a schedule of treatment that produces marked and similar topical anti-inflammatory activity, the amount of alpha-humulene absorbed in the ear was very similar (about 2 microg/ear). It is concluded that alpha-humulene exhibited a rapid onset and relatively good absorption following oral and topical administration. Taken together, these findings further contribute to an explanation of the topical and systemic anti-inflammatory and antinociceptive properties previously reported for the essential oil and for alpha-humulene obtained from Cordia verbenacea, they also provide support for the clinical studies conducted with the phytomedicine Acheflan.     

维甲酸脂质体在小鼠体内的药物动力学及组织分布

目的考察2种全反式维甲酸(ATRA)脂质体静脉给药后在小鼠体内的药物动力学和组织分布。方法分别采用不饱和豆磷脂(SPC),以及SPC与聚乙二醇-磷脂酰乙醇胺(PEG-PE)以一定比例混合的混合物为膜材,利用乙醇注入法制备全反式维甲酸普通脂质体和长循环脂质体,静脉注射后采用HPLC法测定小鼠血浆及各组织中的药物浓度。结果普通脂质体和长循环脂质体的AUC分别是以游离药物给药组的2.58倍和5.00倍,t1/2分别由2.66 h延长至3.74 h和6.39 h,脂质体在肝中分布显著增加。结论2种ATRA脂质体能够延缓药物释放,增强药物靶向性。     

新型二膦酸盐药物药动学及组织分布的研究

目的 研究新型二膦酸盐(SC)抗骨质疏松药物在小鼠体内的分布和大鼠体内的药动学及排泄过程.方法 采用99mTc直接标记SC得到99mTe-SC,于大鼠尾静脉注射99mTc-SC后的不同时间取血,测量放射性计数,并计算药动学参数;予小鼠尾静脉注射99Tcm-SC后的不同时间处死,取主要脏器或组织,测定注射剂量率.另收集大鼠给药后不同时段的尿粪和胆汁评价排泄过程.结果 SC在体内的处置符合线性药动学,t1/2约为12 h,表观分布容积和清除率均较小,组织的分布程度低;SC在肝脏内浓聚了较多放射物质,脾脏次之,其余组织中的分布呈低水平;肾脏为SC的主要排泄器官,粪便及胆汁排泄次之.结论 研究为SC提供了药动学的基本数据.     

Absorption, distribution and excretion of a new thienodiazepine derivative (Y-7131) in rats and mice.

The synthesis of radioactive 6-(o-chlorophenyl)-8-ethyl-1-methyl-4H-s-triazolo[3,4-c]thieno[2,3-e][1,4]diazepine (Y-7131), a new psychotropic agent, is descirbed. The labelled compound was rapidly and completely absorbed following oral administration to rats and mice. The blood levels of radioactivity reached maximum at 0.5 h in rats, and 1 h in mice, respectively, and then declined rapidly with biological half-lives of about 1.5 h in both animals, although the level was higher in mice than in rats. Approximately 45% of the radioactivity in the serum was bound to the serum protein at 1 h after oral administration. The dosed radioactivity was almost completely excreted within 3 days. In rats, more radioactivity was excreted in feces than in urine, while the reverse was noted in mice. An extensive biliary excretion of radioactivity was evidenced in rats after oral dosing. The highest concentrations of radioactivity were found in the liver, kidney, and adrenals, while relatively low levels in the brain of rats. The distribution patterns of radioactivity in mice were similar to those in rats except for the serum and liver. No remarkable accumulation of radioactivity in rat tissues was observed by repeated oral doses of the labelled compound for periods up to 21 days. The metabolic pathways of Y-7131 were qualitatively similar in rats and mice, and one of them was demonstrated to be the hydroxylation at alpha-position in the ethyl side chain.     

Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice

Betulinic acid is a naturally occurring pentacyclic triterpenoid. Betulinic acid has recently been selected by the National Cancer Institute for addition into the RAID (Rapid Access to Intervention in Development) programme. The agent exhibits potential anti-tumour activity and functions in this regard via apoptosis. The objective of the present study was to determine the pharmacokinetics of betulinic acid in CD-1 mice. Serum samples were obtained at designed times after a single 250 or 500 mg/kg intraperitoneal (IP) dose of betulinic acid. Tissue samples (skin, heart, liver, spleen, kidney, lung, brain, colon, caecum, ovary, uterus, thymus, lymph node, bladder, perirenal fat, mammary gland and small intestine) were collected after betulinic acid administration (500 mg/kg). Betulinic acid was extracted with methylene chloride and quantitatively analysed by HPLC/MS. Oleanolic acid and madecassic acid were used as internal standards. Pharmacokinetic parameters were calculated using the WinNonlin pharmacokinetic software package. A two-compartment, first-order model was selected for pharmacokinetic modelling. The results showed that after IP 250 and 500 mg/kg betulinic acid, the serum concentrations reached peaks at 0.15 and 0.23 h, respectively. The 250 and 500 mg/kg above betulinic acid IP doses were found to have elimination half-lives of 11.5 and 11.8 h and total clearances of 13.6 and 13.5 L/kg/h, respectively. The pharmacokinetic parameters observed for IP betulinic acid 500 mg/kg in the skin of mice were as follows: k(a) (h(-1)) 0.257, k(10) (h(-1)) 0.234, t(1/2(alpha)) (h) 2.63, t(1/2(beta)) (h) 20.2, V (L/kg) 0.61, AUC (microg/h/mL) 3504, T(max) (h) 3.90 and C(max) (microg/mL) 300.9. The distribution of betulinic acid in tissues at 24 h post-IP administration in a descending order was as follows: perirenal fat, ovary, spleen, mammary gland, uterus, bladder, lymph node, liver, small intestine, caecum, lung, thymus, colon, kidney, skin, heart and brain.     

重组人白细胞介素－3在小鼠体内的药代动力学及组织分布

用Ｉｏｄｏｇｅｎ法制备１２５Ｉ－γｈＩＬ－３。产品用ＳｅｐｈａｄｅｘＧ－５０凝胶过滤纯化。流出的组分用ＳＤＳ－ＰＡＧＥ测定纯度。选取放化纯度高于９５％的进行药代动力学研究。在ｉＶ剂量为５００、１０００及２５００ｎｇ·ｍｏｕｓｅ－１的１２５Ｉ－γｈＩＬ－３后，浓度－时间曲线按三房室模型拟合，其快分布相约为２ｍｉｎ。慢分布相约为５０ｍｉｎ。终末消除相为８ｈ左右。ＡＵＣ与剂量呈较好的线性关系（ｒ＝０．９９７０）。ｉｍ１２５Ｉ－γｈＩＬ－３１０００ｎｇ·ｍｏｕｓｅ－１后浓度一时间曲线符合一室一级吸收，绝对生物利用度为０．８８，达峰浓度，时间分别为４２．７６μｇ·Ｌ－１和０．５０ｈ。ｉｖ１５ｍｉｎ后，在肾脏中的浓度最高，２４ｈ内排出约８６％的标记药物。     

Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-alpha in mice

The serum pharmacokinetics and the major organs of accumulation of recombinant human tumor necrosis factor-alpha (rHuTNF) were determined in BDF1 mice after intravenous and intramuscular administration. Serum concentrations of immunoreactive protein were determined by enzyme-linked immunosorbent assay, and radioactivity was quantitated by beta and gamma scintigraphy. The serum pharmacokinetics of labeled and unlabeled rHuTNF were identical when administered by the intravenous route. After intravenous doses of 165 to 320 micrograms/kg, the clearance was 2.9-3.6 ml/hr, the initial volume of distribution was 1.4-1.6 ml (70-80 ml/kg), and the half-life was 18.5-19.2 min. Intramuscular administration of 320 micrograms/kg resulted in a peak serum concentration of 112 ng/ml. The time of the peak concentration was 1 hr, and the bioavailability of the intramuscular dose was 12%. The data suggest that the disposition of this protein may be biexponential. If this is the case, the terminal phase would appear to account for less than 1% of the total AUC. Since serum concentrations in the terminal phase are at the sensitivity limit of the assay, a single half-life is reported. 125I-Labeled and metabolically labeled 3H-rHuTNF were used to examine tissue distribution. After intravenous 125I-rHuTNF administration, the rank order of accumulation of the 125I-radiolabel in the major organs (per cent dose per organ over 1440 min) was: liver greater than kidney greater than lung greater than heart greater than spleen. This rank order of accumulation was confirmed by intravenous 3H-rHuTNF administration.(ABSTRACT TRUNCATED AT 250 WORDS)     

Pharmacokinetics and tissue distribution of a water-soluble flavonol triglycoside, CTN986, in mice

The pharmacokinetics and bioavailability of CTN986, a highly water-soluble flavonol triglycoside that has shown interesting antidepressant effects, were determined in mice after intravenous ( I. V.), intraperitoneal ( I. P.) and oral administrations. Concentrations of CTN986 in the biological samples were determined by a validated LC/MS/MS method. Non-compartmental methods were used to perform pharmacokinetic data analysis. The dose-dependent pharmacokinetics of CTN986 was characterized after I. V. administrations (0.16, 0.4 and 1.0 mg/kg) to mice. There was no significant difference in clearance (CL) with increasing dose [252.66 +/- 42.82 mL/h (0.16 mg/kg) versus 241.73 +/- 14.93 mL/h (1.0 mg/kg)] after I. V. administrations. The absolute bioavailability of CTN986 after I. P. and oral administrations was 96.57 % and 1.31 %, respectively. CTN986 was found to distribute widely in the internal organs of mice 10 min after oral dosage, with tissue concentrations in the order of duodenum, stomach, small intestine, kidney, lung, liver, brain, heart and spleen (from the highest to the lowest). In conclusion, CTN986 could be absorbed and extensively distributed into tissues as its intact form in mice.     

Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice

1. Administration of aerosolized, radiolabelled Moli1901 (duramycin, 2622U90), a 19 amino acid polycyclic peptide, to rats resulted in the deposition of high amounts of radiolabel in the respiratory tract, with deposited radiolabel persisting almost unchanged through 7 days after dosing. Little to no radiolabel was present in the bloodstream of these rats. 2. Rats absorbed little radiolabel after p.o. administration, with nearly all of the dose excreted in the faeces by 2 days after dosing. 3. At 7 days following an intravenous dose, rats excreted 54% of the radiolabel in faeces and 5.4% in the urine, with 44% remaining in the carcass, primarily in the liver (33%). 4. Following an intratracheal instillation dose to rats, radiolabel was eliminated from the pulmonary system with a half-life of 64 days. Excretion was almost exclusively via faeces, with an elimination half-life of 52 days. Plasma and blood concentrations in these animals were uniformly <1 ng eq. ml(-1) at all sampling times. 5. Results in mice given intravenous and oral doses were consistent with those observed in rats. 6. Prolonged retention of Moli1901 in pulmonary tissue supports its use in the treatment of respiratory diseases.     

Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice

1. Administration of aerosolized, radiolabelled Moli1901 (duramycin, 2622U90), a 19 amino acid polycyclic peptide, to rats resulted in the deposition of high amounts of radiolabel in the respiratory tract, with deposited radiolabel persisting almost unchanged through 7 days after dosing. Little to no radiolabel was present in the bloodstream of these rats. 2. Rats absorbed little radiolabel after p.o. administration, with nearly all of the dose excreted in the faeces by 2 days after dosing. 3. At 7 days following an intravenous dose, rats excreted 54% of the radiolabel in faeces and 5.4% in the urine, with 44% remaining in the carcass, primarily in the liver (33%). 4. Following an intratracheal instillation dose to rats, radiolabel was eliminated from the pulmonary system with a half-life of 64 days. Excretion was almost exclusively via faeces, with an elimination half-life of 52 days. Plasma and blood concentrations in these animals were uniformly <1 ng eq. ml <1 at all sampling times. 5. Results in mice given intravenous and oral doses were consistent with those observed in rats. 6. Prolonged retention of Moli1901 in pulmonary tissue supports its use in the treatment of respiratory diseases.     

Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice

AIM: To study the pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes (5-Fu-GCL) in mice. METHODS: The concentration of 5-fluorouracil (5-Fu) in serum was detected by high performance liquid chromatography after 5-Fu-GCL (80, 40, 20 mg/kg) and free 5-Fu (40 mg/kg) were injected intravenously into mice. The tissue distribution of 5-Fu-GCL (40 mg/kg) and free 5-Fu (40 mg/kg) was investigated, and concentration-time profile of the two preparations in the liver were studied. Data were analyzed by 3p97 program. RESULTS: Serum concentration-time curves of 5-Fu-GCL and free 5-Fu conformed to one compartment model of first order absorption. 5-Fu-GCL at 80, 40, and 20 mg/kg had T(1/2Ke) of 25.8+/-4.2, 27.3+/-4.4, and 28.2+/-5.6 min; C0 of 24.9+/-4.9, 17.7+/-3.6, and 11.5+/-2.7 mg/L; and AUC of 990.0+/-45.2,622.5+/-38.3, and 340.4+/-25.6 mg x min x L(-1), respectively. In contrast free 5-Fu at 40 kg/mg had T(1/2Ke) of 15.8+/-2.2 min, C0 of 35.8+/-6.2 mg/L, AUC of 639.0+/-35.9 mg x min x L(-1). The tissue distribution of 5-Fu-GCL in the liver and immune organs was significantly increased, while in heart and kidney it was remarkably decreased. The AUC of 5-Fu-GCL in the liver was 3 times higher than that of free 5-Fu. CONCLUSION: The pharmacokinetics and tissue distribution of 5-Fu-GCL appears to be linear-related and dose-dependent, and exhibits sustained-release and hepatic target characteristics.     

Pharmacokinetics and tissue distribution profile of icariin propylene glycol-liposome intraperitoneal injection in mice

Objectives The pharmacokinetics and tissue distribution of icariin propylene glycol‐liposome suspension (ICA‐PG‐liposomes) have been investigated. Methods ICA‐PG‐liposomes or ICA‐PG‐solution were prepared and intraperitoneally injected to mice. Morphology and size distribution of ICA‐PG‐liposomes were observed by transmission electron microscopy (TEM) and laser particle sizer. Plasma and tissues were collected at different times after intraperitoneal injection and icariin concentrations were determined by HPLC. Key findings From TEM, ICA‐PG‐liposomes showed spherical vesicles with a mean particle size of 182.4 nm. The encapsulation efficiency of ICA‐PG‐liposomes reached 92.6%. Pharmacokinetics of ICA‐PG‐liposomes displayed the three open compartments model. ICA‐PG‐liposomes enhanced icariin absorption from the abdominal cavity, prolonged mean retention time (MRT_(0‐t)), increased area under curve (AUC_(0‐t)) and maximum concentration in plasma. Compared with ICA‐PG‐solution, ICA‐PG‐liposomes resulted in larger amounts of icariin being distributed into spleen (60.38% total icariin), liver (16.68%), lung (6.21%), kidney (4.64%), heart (1.43%) and brain (1.83%). AUC_(0‐t) values in most tissues (except lung) of mice administered ICA‐PG‐liposomes were higher than those administered ICA‐PG‐solution, while Clearance in most tissues (except brain and lung) decreased. The MRT_(0‐t) values of ICA‐PG‐liposomes in all tissues and half lives of most tissues (except brain) were prolonged. From Targeted efficiency and relative uptake data, the spleen was the target tissue of the ICA‐PG‐liposomes. Conclusions ICA‐PG‐liposomes changed the pharmacokinetic behaviour and enhanced icariin distribution in tissues. With nanometer size, high encapsulation efficiency and improved pharmacokinetics, ICA‐PG‐liposomes might be developed as promising carriers for icariin injection.